Clinicopathological Features and Prognosis of Primary GISTs with Tumor Rupture in the Real World

Overview

Journal Ann Surg Oncol

Publisher Springer

Specialty Oncology

Date 2018 May 13

PMID 29752602

Citations 21

Authors

Toshirou Nishida

Haruhiko Cho

Seiichi Hirota

Toru Masuzawa

Gaku Chiguchi

Toshimasa Tsujinaka

Affiliations

Soon will be listed here.

Abstract

Background: Patients with ruptured gastrointestinal stromal tumor (GIST) are recommended for imatinib adjuvant therapy; however, their clinicopathological features and prognosis in the era of imatinib are unknown.

Patients And Methods: The study cohort included 665 patients with histologically proven primary GISTs who underwent R0 or R1 surgery between 2003 and 2007; the validation cohort included 182 patients between 2000 and 2014. The definitions of tumor rupture in the study included perforation at tumor site, tumor fracture, piecemeal resection including open biopsy, and macroscopic injuries to the pseudocapsule.

Results: Tumor rupture occurred in 21 (3.2%) of 665 and 5 (2.9%) of 182 patients in the study and validation cohort, respectively. Ruptured GISTs were more symptomatic, were larger in size, and had higher mitotic count than nonruptured GISTs but were not associated with tumor location or laparoscopic surgery. GISTs with intraoperative rupture had clinicopathological features and prognostic outcomes similar to those with preoperative rupture. Recurrence rates were higher and median recurrence-free survival (RFS) and overall survival (OS) were shorter with ruptured than nonruptured GIST. Tumor rupture was one of the independent prognostic factors for RFS, but not OS, according to multivariate analysis.

Conclusions: Ruptured GISTs were symptomatic larger tumors with high mitotic activity, frequent relapse, and shorter RFS. Tumor rupture was an independent prognostic factor for RFS, but not for OS, in the era of imatinib.

Citing Articles

Impact of Mutation Profile on Outcomes of Neoadjuvant Therapy in GIST.

Mohammadi M, Roets E, Bleckman R, Oosten A, Grunhagen D, Desar I Cancers (Basel). 2025; 17(4).

PMID: 40002229 PMC: 11852491. DOI: 10.3390/cancers17040634.

Understanding Gastric GIST: From Pathophysiology to Personalized Treatment.

Moga D, Vladoiu G, Fratila A, Dan A, Popa D, Oprea V J Clin Med. 2024; 13(14).

PMID: 39064037 PMC: 11277334. DOI: 10.3390/jcm13143997.

Survival of patients with ruptured gastrointestinal stromal tumour treated with adjuvant imatinib in a randomised trial.

Joensuu H, Reichardt A, Eriksson M, Hohenberger P, Boye K, Cameron S Br J Cancer. 2024; 131(2):299-304.

PMID: 38862742 PMC: 11263706. DOI: 10.1038/s41416-024-02738-z.

Adjuvant therapy for rare rectal gastrointestinal stromal tumors: A case report.

Chu T, Pu T, Chen C Clin Case Rep. 2024; 12(4):e8774.

PMID: 38634096 PMC: 11021600. DOI: 10.1002/ccr3.8774.

Factors associated with gastrointestinal stromal tumor rupture and pathological risk: A single-center retrospective study.

Liu J, Jia Z, Sun L World J Radiol. 2024; 15(12):350-358.

PMID: 38179203 PMC: 10762522. DOI: 10.4329/wjr.v15.i12.350.

References

Kim J, Kim H, Park S, Lee J, Kim A, Ha H . Computed tomography features and predictive findings of ruptured gastrointestinal stromal tumours. Eur Radiol. 2016; 27(6):2583-2590. DOI: 10.1007/s00330-016-4515-z. View

Joensuu H, Eriksson M, Hall K, Hartmann J, Pink D, Schutte J . One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA. 2012; 307(12):1265-72. DOI: 10.1001/jama.2012.347. View

Miettinen M, Lasota J . Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006; 23(2):70-83. DOI: 10.1053/j.semdp.2006.09.001. View

Takahashi T, Nakajima K, Nishitani A, Souma Y, Hirota S, Sawa Y . An enhanced risk-group stratification system for more practical prognostication of clinically malignant gastrointestinal stromal tumors. Int J Clin Oncol. 2007; 12(5):369-74. DOI: 10.1007/s10147-007-0705-7. View

Bischof D, Kim Y, Behman R, Karanicolas P, Quereshy F, Blazer 3rd D . A nomogram to predict disease-free survival after surgical resection of GIST. J Gastrointest Surg. 2014; 18(12):2123-9. PMC: 4659361. DOI: 10.1007/s11605-014-2658-2. View

Verduijn M, Grootendorst D, Dekker F, Jager K, le Cessie S . The analysis of competing events like cause-specific mortality--beware of the Kaplan-Meier method. Nephrol Dial Transplant. 2010; 26(1):56-61. DOI: 10.1093/ndt/gfq661. View

Joensuu H, Vehtari A, Riihimaki J, Nishida T, Steigen S, Brabec P . Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol. 2011; 13(3):265-74. DOI: 10.1016/S1470-2045(11)70299-6. View

Yamamoto K, Tsujinaka T, Takahashi T, Sato S, Nishiguchi Y, Nakashima Y . Impact of the Japanese gastric cancer screening system on treatment outcomes in gastric gastrointestinal stromal tumor (GIST): an analysis based on the GIST registry. Ann Surg Oncol. 2014; 22(1):232-9. DOI: 10.1245/s10434-014-3971-4. View

Ng E, Pollock R, Munsell M, Atkinson E, Romsdahl M . Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg. 1992; 215(1):68-77. PMC: 1242372. DOI: 10.1097/00000658-199201000-00010. View

10.

Rutkowski P, Nowecki Z, Michej W, Debiec-Rychter M, Wozniak A, Limon J . Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumor. Ann Surg Oncol. 2007; 14(7):2018-27. DOI: 10.1245/s10434-007-9377-9. View

11.

Yanagimoto Y, Takahashi T, Muguruma K, Toyokawa T, Kusanagi H, Omori T . Re-appraisal of risk classifications for primary gastrointestinal stromal tumors (GISTs) after complete resection: indications for adjuvant therapy. Gastric Cancer. 2014; 18(2):426-33. DOI: 10.1007/s10120-014-0386-7. View

12.

Rutkowski P, Bylina E, Wozniak A, Nowecki Z, Osuch C, Matlok M . Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour - the impact of tumour rupture on patient outcomes. Eur J Surg Oncol. 2011; 37(10):890-6. DOI: 10.1016/j.ejso.2011.06.005. View

13.

Nishida T, Blay J, Hirota S, Kitagawa Y, Kang Y . The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines. Gastric Cancer. 2015; 19(1):3-14. PMC: 4688306. DOI: 10.1007/s10120-015-0526-8. View

14.

Joensuu H . Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol. 2008; 39(10):1411-9. DOI: 10.1016/j.humpath.2008.06.025. View

15.

Goh B, Chow P, Yap W, Kesavan S, Song I, Paul P . Which is the optimal risk stratification system for surgically treated localized primary GIST? Comparison of three contemporary prognostic criteria in 171 tumors and a proposal for a modified Armed Forces Institute of Pathology risk criteria. Ann Surg Oncol. 2008; 15(8):2153-63. DOI: 10.1245/s10434-008-9969-z. View

16.

Casali P, Cesne A, Velasco A, Kotasek D, Rutkowski P, Hohenberger P . Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup.... J Clin Oncol. 2015; 33(36):4276-83. DOI: 10.1200/JCO.2015.62.4304. View

17.

Holmebakk T, Bjerkehagen B, Boye K, Bruland O, Stoldt S, Hall K . Definition and clinical significance of tumour rupture in gastrointestinal stromal tumours of the small intestine. Br J Surg. 2016; 103(6):684-691. DOI: 10.1002/bjs.10104. View

18.

DeMatteo R, Ballman K, Antonescu C, Corless C, Kolesnikova V, von Mehren M . Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial. Ann Surg. 2013; 258(3):422-9. PMC: 4041735. DOI: 10.1097/SLA.0b013e3182a15eb7. View

19.

Gold J, Gonen M, Gutierrez A, Broto J, Garcia-Del-Muro X, Smyrk T . Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol. 2009; 10(11):1045-52. PMC: 3175638. DOI: 10.1016/S1470-2045(09)70242-6. View

20.

Fletcher C, Berman J, Corless C, Gorstein F, Lasota J, Longley B . Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol. 2002; 33(5):459-65. DOI: 10.1053/hupa.2002.123545. View